Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- XERS +8.9% (raises FY23 guidance)
Other news:
- RARE +11.9% (Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta)
- PRLD +8.7% (Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference)
- LULU +5.6% (to join S&P 500)
- RAD +4.9% (initiates voluntary Chapter 11 process; receives commitment for $3.45 bln in new financing to support business operations; appoints Jeffrey Stein as CEO)
- ORLA +4.6% (provides third quarter 2023 operational results and increases 2023 annual gold production guidance) PAX +4.5% (acquires Private Equity Solutions Business from abrdn)
- DBVT +3.4% (appoints Virginie Boucinha as CFO)
- MLTX +3.3% (announces the full dataset from its 24-week MIRA clinical trial establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa)
- IMUX +3.3% (Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023)
- ESTA +3.2% (announces FDA clearance of motiva flora smoothsilk tissue expander)
- EGY +3.1% (provides operational and financial update including production and sales volumes for Q3)
- CHRS +3.1% (Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics)
- CVS +2.3% (Percentage of Aetna Medicare Advantage members in 4+ Star plans is expected to increase to 87%; expects to be eligible for bonus payments)
- HUBB +2.2% (to join S&P 500)
- NN +2% (files for 4768491 shares of common stock by selling shareholders)
- RYAM +1.8% (to explore potential sale of its paperboard and high-yield pulp assets located at its Temiscaming site)
- MRUS +1.7% (Announces Business Update Conference Call)
- ONCY +1.6% (to present two posters on the pelareorep-based GOBLET study at ESMO 2023)
- ALB +1.4% (withdraws non-binding offer to acquire Liontown Resources)
Analyst comments:
- ALHC +10.7% (upgraded to Strong Buy from Outperform at Raymond James )
- PTEN +3.1% (upgraded to Buy from Neutral at BofA Securities)
- VRNS +3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- TRN +2.2% (upgraded to Positive from Neutral at Susquehanna)
- GBX +1.9% (upgraded to Positive from Neutral at Susquehanna)
- W +1.2% (upgraded to Hold from Sell at Loop Capital)
- SBRA +1% (upgraded to Equal Weight from Underweight at Wells Fargo)